KYinno

What KYinno does

KYinno Biotechnology (康源博创生物科技) is a preclinical contract research organization founded in 2017 and headquartered in the Yizhuang BioPark in Beijing, China, with a North American operational office in Woburn, Massachusetts. The company provides customized in vitro and in vivo pharmacology, cell line engineering, therapeutic target identification, and antibody discovery services to global pharmaceutical and biotechnology clients, with a stated base of 200+ global users and 700+ partners.

The technical core consists of proprietary transgenic mouse platforms — KY-CLC (common light chain) and KY-HC (heavy chain/nanobody) — for bispecific, trispecific, and nanobody antibody discovery; a bank of 8,800+ Ba/F3 kinase engineered cell lines (expanding by 1,000+ annually); the MPSA-AB5000 membrane protein screening panel covering 5,465 human targets for off-target antibody specificity testing; and the KY-AI™ antibody development platform. The Innopedia database consolidates 600+ tumor cell lines, 700+ engineered cell lines, ~2,000 anti-tumor drug efficacy records, and 100+ standard antibodies with 30+ analysis modules. The KY-CLC platform was used to support Bio-Thera's EGFR/HER3 bispecific ADC, the world's first bispecific ADC to advance to Phase III clinical trials.

KYinno generates revenue through project-based preclinical CRO contracts, one-time sales of catalog engineered cell lines and antibodies, and customized cell line construction services. Pricing is quote-based and not publicly disclosed. Go-to-market is sales-led and direct, with dedicated business development contacts for US ([email protected], +1 617-937-9720) and China (010-58222701) markets, supplemented by scientific conference presence at AACR, EORTC, and SABPA and content marketing via the company blog and webinars. The company has raised approximately $60.8 million across four funding rounds through December 2025.

Name

KYinno

Legal name

康源博创生物科技(北京)有限公司

Website

https://kyinno.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

51–100 employees

Short description

KYinno is a Beijing-headquartered preclinical CRO, founded in 2017, that provides engineered cell lines, antibody discovery, and in vitro/in vivo pharmacology services to global pharmaceutical and biotech companies developing oncology therapeutics, anchored by proprietary KY-CLC and KY-HC transgenic mouse platforms.

Ownership category

akta.pro rank

Product category

Preclinical Contract Research Services (Drug Discovery)

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Specialty Therapeutic-Area CROs (e.g., oncology/rare disease) (HLAGAAAL)

akta.pro secondary industry

Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization) (HLAAAIAC)

Keywords

• Preclinical CRO services
• Engineered cell lines
• Antibody discovery
• Oncology drug development
• In vivo pharmacology

Headquarters

HQ city

Beijing

HQ country

China

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Contract Research Services (CRO): Preclinical contract research organization providing customized services including in vitro pharmacology, in vivo pharmacology, cell line engineering, therapeutic target identification, and antibody discovery on a project-by-project basis for pharma and biotech clients
2. Engineered Cell Line Products: Sale of engineered cell lines including kinase cell lines, immune molecule cell lines, gene editing cell lines, reporter cell lines, fluorescence labeled cell lines, drug resistant cell lines, and tumor antigen cell lines
3. Antibody Products: Sale of antibody products including hybridoma, isotype controls, recombinant proteins, reference antibodies, and customized antibody production services

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

KYinno is a preclinical contract research organization (CRO) providing customized in vitro and in vivo pharmacology, cell line engineering, therapeutic target identification, and antibody discovery services for pharmaceutical and biotech clients. The company sells engineered cell lines (kinase, immune molecule, gene editing, reporter, cancer), antibody products, and proprietary platforms including the KY-CLC common light chain mouse, KY-HC nanobody mouse, MPSA-AB5000 panel, and KY-AI antibody development AI platform.

Product overview

KYinno is a preclinical contract research organization (CRO) providing a comprehensive portfolio of products and services for drug discovery. The offering consists of engineered cell lines (3,000+ in-house, expanding by 1,000+ yearly), cancer cell lines (human and animal), antibodies (hybridoma, recombinant, reference), and multiple technology platforms including the MPSA-AB5000 membrane protein screening panel (5,000+ targets), KY-AI™ AI antibody development platform, Multispecific Antibody Development Platform (bispecific/trispecific via KY-CLC™ and KY-HC™ mouse platforms), and the Innopedia database. Services span in vitro and in vivo pharmacology, antibody discovery, drug combination screening, and customized cell line construction.

Differentiator

Problem solved

Functional benefit

Brands

• Innopedia: A proprietary database covering tumor cell lines, engineered cell lines, and standard antibodies for research support.
• KY-AI
• KY-CLC
• KY-HC

Products and services

• Engineered Cell Lines Catalog of engineered cell lines and mouse tumor models including kinase cell lines, immune molecule cell lines, gene editing cell lines, reporter cell lines, fluorescence labeled cell lines, drug resistant cell lines, and tumor antigen cell lines for pharmaceutical and biotech research use.
• Cancer Cell Lines Human and animal cancer cell line models supporting investigations in cancer biology, drug discovery, and pharmacology research for pharmaceutical and biotech clients.
• Antibodies Catalog of antibody products including hybridoma, isotype controls, recombinant proteins, reference antibodies, and customized antibody production services for research use.
• Ba/F3 Kinase Cell Lines Ba/F3 kinase stable cell lines for kinase-focused drug discovery. The platform includes over 8,800 stable cell lines with 1,100+ additional lines under development for evaluating kinase transforming ability, downstream signaling, high-throughput screening, PROTAC evaluation, and drug resistance mutation screening.
• MPSA-AB5000 Membrane Protein Screening Panel Membrane protein screening array covering 5,465 human membrane protein targets expressed on living cell surfaces for antibody specificity and off-target screening in drug discovery programs.
• KY-AI Antibody Development Platform Artificial intelligence platform for antibody development supporting target identification, screening, optimization, and developability assessment including stability, solubility, and immunogenicity predictions for therapeutic antibody discovery.
• Multispecific Antibody Development Platform (KY-CLC and KY-HC) Platform for developing bispecific and tri-specific antibodies using proprietary KY-CLC common light chain transgenic mouse and KY-HC heavy chain (nanobody) transgenic mouse platforms, supporting antibody therapeutics development.
• Innopedia Database Proprietary research database covering tumor cell lines, engineered cell lines, and standard antibodies with integrated pharmacogenomic and pharmacological data on nearly 2,000 anti-tumor drugs and 30+ analysis modules for research intelligence.
• In Vitro Pharmacology Services Preclinical in vitro pharmacology services including cell proliferation assays, MegaScreen screening, organoid studies, internalization assays, ELISA, FACS binding assays, immuno-oncology assays, and ADCC/ADCP assays for pharmaceutical and biotech clients.
• In Vivo Pharmacology Services In vivo pharmacology services including Ba/F3 xenograft models, gene-editing xenograft models, luciferase tumor models, PBMC humanized mouse models, syngeneic models, orthotopic models, subcutaneous models, and metastasis models for preclinical drug efficacy studies.
• Antibody Discovery Services Customized antibody discovery services including common light chain platform screening, nanobody discovery service, AI-based antibody engineering, and membrane protein antibody off-target screening for therapeutic antibody developers.
• Drug Combination Services Drug combination screening services for both in vitro and in vivo combination studies evaluating synergistic effects of therapeutic combinations for cancer drug discovery.
• Customized Cell Line Construction Customized stable cell line development service providing high quality, fully validated, cost effective cell line construction with short turnaround times for genetic mechanism investigation, disease modeling, and therapeutic development.

Quantifiable outcome

• Over 8,800 Ba/F3 kinase stable cell lines available for drug discovery
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature8 records

Scale indicators7 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Crown Bioscience: Preclinical CRO with deep oncology focus offering in vivo pharmacology, xenograft models, and cell line services — directly comparable to KYinno's preclinical oncology CRO model, though at significantly larger scale.
• AbCellera Biologics: Antibody discovery platform combining transgenic mice, AI/ML, and high-throughput screening to discover therapeutic antibodies — directly analogous to KYinno's KY-CLC/KY-HC mouse platforms plus KY-AI stack.
• GenScript ProBio: CDMO/CRO offering cell line engineering, antibody discovery, plasmid/gene synthesis, and preclinical services — directly comparable service portfolio to KYinno's cell lines, antibody, and in vitro/in vivo offerings.
• Sino Biological: China-based reagent manufacturer of recombinant proteins, antibodies, and cell line products for research — directly comparable to KYinno's catalog cell line and antibody product business.
• LakePharma (Curia): Preclinical CRO specializing in antibody discovery, protein engineering, and cell line development — directly comparable to KYinno's antibody discovery and engineering service offering.

Broad incumbents

• Bio-Techne: Large life-science reagent and instrument provider with significant catalog cell lines, antibodies, and recombinant proteins — overlaps with KYinno's product catalog but operates at much broader scale across many research areas.
• WuXi AppTec: Global CRO/CDMO giant offering preclinical through clinical services including cell line engineering and in vivo pharmacology — overlapping preclinical capabilities but vastly broader portfolio than KYinno.
• Pharmaron: Integrated CRO/CDMO with preclinical pharmacology, cell line, and antibody services — comparable in service breadth but at a substantially larger scale and global footprint.

Emerging players

• ATUM: Gene synthesis and protein engineering company offering custom antibody and enzyme engineering services — meaningful overlap with KYinno's antibody engineering capability though smaller scale.
• Absolute Antibody: Recombinant antibody manufacturer and engineering service provider — comparable in recombinant antibody production capability but focused on reagent-grade rather than therapeutic discovery CRO work.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/kyinno/posts/?feedView=all
• Xx.com/kyinno_com

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds4 records

Investors14 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about KYinno